{"uid":"cap_NJxGiEC4IYsNPcRCLrEjY","slug":"clinicalintelpulse-sponsor-pipeline-intelligence-54525278","name":"ClinicalIntelPulse Sponsor Pipeline Intelligence","description":"Pharma/biotech company pipeline intelligence — full drug pipeline by phase, therapeutic-area coverage, FDA approval history, partnerships, competitive positioning and investment catalysts for any sponsor. Worldwide. For investor and M&A agents.","url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/sponsor-intel","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"focus":{"type":"string"},"sponsor":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}},"responseSchema":{"type":"json","example":{"fda_approvals":[{"drug":"Patisiran (Onpattro)","type":"NDA","approved":"2018","indication":"hATTR polyneuropathy","first_in_class":true},{"drug":"Givosiran (Givlaari)","type":"NDA","approved":"2019","indication":"Acute hepatic porphyria"}],"phase3_assets":[{"drug":"Vutrisiran (Amvuttra)","nctId":"NCT04153149","status":"ACTIVE_NOT_RECRUITING","condition":"ATTR Cardiomyopathy","completion":"2025-Q3","significance":"Key label expansion into ATTR-CM — $3B+ market"}],"query_summary":{"focus":"all","sponsor":"Alnylam Pharmaceuticals"},"pipeline_summary":{"phase1_count":8,"phase2_count":9,"phase3_count":6,"total_active_trials":23,"primary_therapeutic_areas":["Rare genetic diseases (TTR, PH1, AHP)","Cardiovascular (inclisiran)","CNS (Huntington's)"]},"investment_signals":{"risks":["Pricing pressure in rare disease","RNAi delivery competition from Arrowhead"],"near_term_catalysts":["HELIOS-B ATTR-CM readout 2025","ALN-APP Phase 2 for early Alzheimer's"],"pipeline_value_estimate":"$12-18B risk-adjusted NPV"},"competitive_position":"Global leader in RNAi therapeutics. 6 approved drugs. Patent portfolio dominant through 2035+.","partnership_activity":"Novartis partnership (inclisiran, cardiovascular) — $9.7B deal. Roche collaborations ongoing. Regeneron RNAi collaboration $400M+."}},"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.2","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.2/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.2","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.2","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_oLqG1byqwnydllxf6IaEc","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.2","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Returns a comprehensive drug pipeline intelligence report for a given pharma/biotech sponsor — covering pipeline phases, therapeutic areas, FDA approval history, partnerships, competitive positioning, and investment catalysts.","exampleAgentPrompt":"Pull the full pipeline intelligence report for Vertex Pharmaceuticals — I want their drug pipeline broken down by clinical phase, therapeutic area coverage, FDA approval history, any major partnerships, and the top investment catalysts I should be watching.","exampleUseCases":[{"title":"Competitive positioning before investor call","prompt":"I'm prepping for a call with a biotech investor tomorrow — can you pull the full pipeline intelligence for Exelixis? Break down their pipeline by phase, show me their FDA approval track record, and highlight any major partnerships or deals they've announced. I need to know where they stand competitively against Incyte and what catalysts might move the stock."},{"title":"M&A due diligence target assessment","prompt":"We're evaluating a mid-cap oncology company as an acquisition target. Can you get me a comprehensive pipeline report for Agios Pharmaceuticals? I need their full drug portfolio by clinical phase, therapeutic area focus, partnership details, and what near-term regulatory wins or setbacks might affect valuation."},{"title":"Investment thesis research for equity analysis","prompt":"I'm building an investment thesis on rare disease biotechs and Ultragenyx keeps coming up. Give me their complete pipeline breakdown by phase, their track record with FDA approvals, recent partnership announcements, and the key catalysts coming up in the next 12-18 months so I can assess the upside potential."}],"resultDescription":"A structured intelligence report for the requested sponsor including: full drug pipeline organized by clinical phase (Phase 1 through NDA/BLA), therapeutic area coverage map, historical FDA/EMA approval track record, active and recent partnerships or licensing deals, competitive positioning narrative, and near-term investment catalysts — all sourced from global clinical registries and regulatory databases.","failureModes":["Unknown or misspelled sponsor name returns empty or low-confidence results","Small or private sponsors with limited public trial data may return sparse pipelines","Recently renamed or merged companies may not match historical records","Non-English or non-Romanized sponsor names may require normalization","Rate limiting or payment failure may return 402/429 errors"],"whenToPreferThis":"Use this endpoint when you need a comprehensive, sponsor-level view of a pharma or biotech company's pipeline for investment research, M&A due diligence, or competitive benchmarking. Prefer this over disease-level endpoints when the research question centers on a specific company rather than a therapeutic area or disease. Ideal for investor agents, equity analysts, and M&A teams that need a rapid 360-degree view of a sponsor's clinical and regulatory standing.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-14T00:36:19.954Z","isFirstParty":false}